Generation and characterization of hiPSC
Working group 2 is responsible for the generation and characterization of hiPSC. The team shall compare and optimize the methodologies for the generation of hiPSC suitable for the manufacture of therapeutic products and develop a Standard Operating Procedure (SOP) on hiPSC generation from haplo-selected cord blood samples based on assessment of cell preparation/selection and reprogramming methods.
Objectives
- Comparison and optimisation of methodologies for the generation of hiPSC suitable for the manufacture of therapeutic products
WG2 Leaders
Angel Raya
Margarida Serra
Description of Work
T2.1
Literature review on reprogramming methodologies for hiPSC generation from haplo-selected CB samples and reprogramming and regulatory experts meeting selection of the most suitable method for reprogramming.
T2.2
Literature review and consultation with expert networks on hiPSC characterisation criteria and reprogramming experts meeting selection of the hiPSC characterisation criteria.
T2.3
Literature review on production of hiPSC for manufacture of cell-based medicines and reprogramming experts meeting.
Deliverables and milestones
D2.1
Report of existing reprogramming and characterisation methodologies for the selection of the most suitable method for hiPSC generation (M9) D2.2: SOP’s for generation on hiPSC suitable for the manufacture of cell therapy products (M12)
M2.1
Selection of the most suitable method for hiPSC generation from haplo-selected CB samples based on assessment of cell preparation/selection and reprogramming methods suitability for hiPSC- based medicinal products.
M2.2
Selection of hiPSC characterisation criteria.
